Shandong Weigao Group Medical Polymer Co Ltd

1066.HK · Healthcare · Medical Instruments & Supplies · HKD · Fundamentals
Asset-light

Physical assets are 27.9% of total assets, a light footprint. Capex is 0.84x depreciation while free cash flow yield is positive, which can mean an aging base that is still throwing off cash. ROIC is 7.1%, below an 8% cost-of-capital hurdle.

Fixed-asset turnover is 1.78x. Compare it with other names in the same basket.

Physical asset ratio
27.9%
Net PP&E plus inventory, divided by total assets. Above 50% is a heavy footprint.
Fixed asset turnover
1.78x
Revenue per dollar of the physical asset base.
Capex / D&A
0.84x
Above 1.0x means the physical base is being replaced or expanded.
Tangible book / share
$4.65
Assets minus goodwill, intangibles, and liabilities, per share.
Price / tangible book
0.72x
Price $3.35.
Fixed-charge coverage
2.93x
EBITDA minus capex, divided by interest plus short-term debt.
FCF yield
11.4%
Latest free cash flow divided by current market cap ($15.01B).
ROIC
7.1%
After-tax operating income over equity plus debt minus cash. Operating income / net PP&E is 0.23x.

Footprint and return

Turnover and reinvestment

Year Physical FAT Capex/D&A TBV/sh Coverage FCF ROIC EBIT/PP&E
2018 24.0% 1.91x 1.41x $2.02 3.45x $1.42B 11.1% 0.44x
2019 25.8% 1.87x 1.61x $2.51 1.57x $1.34B 13.6% 0.49x
2020 27.7% 1.91x 1.45x $2.93 4.39x $1.70B 12.4% 0.38x
2021 27.8% 1.97x 1.52x $3.49 3.56x $1.92B 15.2% 0.43x
2022 29.0% 1.86x 1.39x $4.00 2.83x $1.10B 13.6% 0.40x
2023 29.2% 1.80x 0.75x $4.19 1.02x $2.11B 9.2% 0.28x
2024 28.4% 1.78x 0.61x $4.44 1.82x $2.19B 10.3% 0.32x
2025 27.9% 1.78x 0.84x $4.65 2.93x $1.72B 7.1% 0.23x
  • Receivables are larger than the physical asset base, so a finance or credit book may sit outside the physical ratio and inside the debt used for coverage.
  • Principal due is the current portion of debt.
Latest year inputs (2025)
Net PP&E: $7.53B
Inventory: $2.52B
Total assets: $36.06B
Goodwill: $3.70B
Intangibles: $1.05B
Liabilities: $10.23B
Tangible book: $21.08B
Shares: 4,538,487,000
Revenue: $13.39B
Capex: $832.64M
D&A: $987.22M
EBITDA: $2.83B
Interest: $249.23M
Short-term debt: $432.61M
Free cash flow: $1.72B
Operating income: $1.70B
Invested capital: $20.24B
Tax rate: 15.8%